Shares of Sharon Bio Medicine surged almost 6% as the company declared that its Taloja plant has been approved by the European drug agency-European Directorate for the Quality of Medicines & Healthcare (EDQM). The company said the move will enhance its sales in Europe and other countries.
Shares of Sharon Bio Medicine are currently trading at Rs 47.50-a-piece up 4.6% or on the Bombay Stock Exchange (BSE). A total of 7,64,838 shares changed hands on both BSE and NSE as compared to its 30-day average trading volume of 6,44,361. The share touched a high of Rs 50.65 and a low of Rs 45.30 during the day.
On Monday, the company, in an exchange said," Sharon Bio-Medicine Ltd has informed BSE that the Company's Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1. This will further enhance the sales to Europe and other countries in near future."
Shares of Sharon Bio Medicine are currently trading at Rs 47.50-a-piece up 4.6% or on the Bombay Stock Exchange (BSE). A total of 7,64,838 shares changed hands on both BSE and NSE as compared to its 30-day average trading volume of 6,44,361. The share touched a high of Rs 50.65 and a low of Rs 45.30 during the day.
On Monday, the company, in an exchange said," Sharon Bio-Medicine Ltd has informed BSE that the Company's Active Pharma Ingredient manufacturing Plant at Plot No. L-6, MIDC, Taloja, near Navi Mumbai Dist. Raigad, Maharashtra has been approved by European Directorate for the Quality of Medicines & Healthcare (EDQM) Council of Europe for complying with the certificate of suitability, as well as the implementation of a suitable Quality Management System based on the Good Manufacturing Practice as laid down in the EU Rules governing Medicinal Product in the European Union, the Company operates in accordance with the requirements of the Resolution AP-CSP (07) 1. This will further enhance the sales to Europe and other countries in near future."